{ "docId": "019de515-4d58-72c5-ae5c-861f6728a8c1", "docSlug": "e797b5cb32b6e19cd9ca01e73bf0fe6c", "documentTitle": "Nuwellis | Investor Presentation Deck | 26 slides", "authorId": "nuwellis", "authorName": "Nuwellis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "pageCount": 26, "prevPage": 13, "nextPage": 15, "slideType": "solution", "function": "present_solution", "density": "overcrowded", "nDataPoints": 20, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de515-4d58-72c5-ae5c-861f6728a8c1/14", "deckHref": "/decks/019de515-4d58-72c5-ae5c-861f6728a8c1", "deckJsonHref": "/decks/019de515-4d58-72c5-ae5c-861f6728a8c1.json", "deckAnchorHref": "/decks/019de515-4d58-72c5-ae5c-861f6728a8c1#slide-14", "components": [ { "bbox": { "h": 0.13, "w": 0.32, "x": 0.04, "y": 0.57 }, "kind": "list", "text": "With inpatient therapy only:\n23% HF patient readmission rate\n$41.7M non reimbursable loss", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0ba248aa-3799-45a6-8ad5-000fc0d78eb1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.13, "w": 0.39, "x": 0.04, "y": 0.75 }, "kind": "list", "text": "With outpatient Aquadex:\n12% HF patient readmission rate\n35% cost savings over inpatient therapy only", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7e463d7c-7da4-4d25-9f57-51b89443d51f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.01, "w": 0.39, "x": 0.01, "y": 0.96 }, "kind": "source-note", "text": "FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2023 Nuwellis, Inc", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "00f0292a-ae80-487b-9a84-369397eb4e3c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.48, "x": 0.48, "y": 0.9 }, "kind": "source-note", "text": "*Figures above are not guaranteed, are used for illustrative purposes only and actual results can and will vary by location", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7dd17331-4eda-4363-abe7-7157724a56a7", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.46, "x": 0.01, "y": 0.93 }, "kind": "source-note", "text": "1. Definitive Health Database for year 2019. 2. Premier Applied Sciences database.", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "dcf01e43-9969-441d-b80f-8296453ddd66", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.48, "x": 0.48, "y": 0.56 }, "kind": "table", "text": "30-DAY READMISSIONS (NON-AQUADEX TREATED PATIENTS) % Readmission Reduction 0% Readmission Reduction (Number of Patients) 0 READMISSION REDUCTION SAVINGS $0", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "151b9548-cd20-4602-9929-ce364b832e47", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.46, "x": 0.01, "y": 0.15 }, "kind": "table", "text": "INPATIENT TREATMENT WITH DIURETICS ONLY ESTIMATED HEART FAILURE (HF) 30-DAY READMISSION COSTS Est Annual HF Admissions¹ 7,537 30-Day Readmission Rate¹ 23% Est Annual HF Readmissions 1,734 Est Cost Per HF Patient Readmission (Inpatient)² $24,027 Est Reimbursement Per HF Readmission (Inpatient) $0 Est Loss Per HF Patient (Inpatient) $24,027 EST LOSS FOR ALL 30-DAY READMISSIONS ($41,662,818)", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6dfbef35-1b8b-4f19-985b-d7b707f39213", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.48, "x": 0.48, "y": 0.44 }, "kind": "table", "text": "30-DAY READMISSIONS (AQUADEX TREATED PATIENTS) % Readmission Reduction 50% Readmission Reduction (Number of Patients) 867 READMISSION REDUCTION COST ($20,831,409)", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7b43b6f9-75dc-4f6a-be03-08729178c989", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.48, "x": 0.48, "y": 0.68 }, "kind": "table", "text": "ADJUSTED REAMISSIONS AND COSTS ADJUSTED READMISSIONS (NUMBER OF PATIENTS) 867 ADJUSTED COSTS FOR READMISSIONS ($20,831,409) NET COSTS FOR ADMINISTRATION OF OUTPATIENT AQUADEX ($6,050,961) TOTAL COSTS FOR OUTPATIENT AQUADEX ($26,882,370) NET SAVINGS OVER INPATIENT THERAPY ONLY $14,780,448 % COST SAVINGS 35% ADJUSTED READMISSION RATE 12%", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "804f00f3-c13c-4cae-b2ec-b3f00252913f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.48, "x": 0.48, "y": 0.32 }, "kind": "table", "text": "ESTIMATED COSTS FOR OUTPATIENT AQUADEX Total Costs (All Patients) ($11,284,433) Total Reimbursement (All Patients) $5,233,472 NET OUPATIENT AQUADEX COSTS (ALL PATIENTS) ($6,050,961)", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8d5d2265-c114-437d-96d3-f1a93cbb2495", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.16, "w": 0.48, "x": 0.48, "y": 0.15 }, "kind": "table", "text": "ESTIMATED PER PATIENT REIMBURSEMENT FOR OUTPATIENT AQUADEX Outpatient Facility Payment $1,216 Venous Access Payment $1,436 Physician Payment $366 TOTAL ESTIMATED REIMBURSEMENT (PER PATIENT) $3,018 NET OUPATIENT AQUADEX COSTS (PER PATIENT) ($3,490)", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fc1a476a-1a73-42e5-9524-684757ad4a9b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.079, "y": 0.06 }, "kind": "title", "text": "Outpatient Aquadex – Potential Savings for a Hospital Account", "attrs": {}, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "626f5d1e-cba2-4514-8a62-43935685246b", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "from": 8, "beatId": "8c08ff5c-89b4-402b-b51f-dc98f2aa4cce", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Slides 8-20 present Nuwellis' solution, including its benefits, traction, and market potential", "position": 2, "confidence": 0.9, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }